RFA-DA-23-048: HEAL Initiative: Research Studies to Develop and Implement Interventions to Prevent Opioid Misuse in Community Health Centers (R61/R33 Clinical Trial Required)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $750,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 8, 2022.
From the official notice on Grants.gov, last changed July 26, 2022. Checked November 7, 2026.
- Award ceiling$750,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- R61, Exploratory/Developmental Phase I. The first phase of a phased award. Moving on to the R33 phase depends on meeting agreed milestones. Other open R61 notices.
- R33, Exploratory/Developmental Grant Phase II. The second phase of a phased award, usually following an R61 or R21 phase. Other open R33 notices.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DA-23-048 in the NIH Guide.
Key dates
| Posted | July 26, 2022 |
|---|---|
| Deadline | November 8, 2022 |
| Archived by Grants.gov | December 14, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the money in the 6 programs behind this notice (71% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
NIH is issuing this Funding Opportunity Announcement (FOA) in response to the declared public health emergency issued by the Secretary, HHS, for the national opioid crisis. This research is part of the Helping to End Addiction Long-term (HEAL) Prevention Initiative, a portfolio of research focused on the prevention of opioid misuse and opioid use disorder funded under NIHs HEAL Initiative. The National Institute on Drug Abuse (NIDA) seeks to address the urgency and magnitude of the opioid crisis by developing and testing new or adapted interventions to prevent opioid misuse among patients served by community health centers (CHCs), and/or developing and testing implementation strategies for screening and referral to preventive interventions for misuse of opioids and other substances among patients served by CHCs. Research will be supported through exploratory/developmental phase awards (R61/R33) that may not exceed 5 years, allocating up to two years of funding for development of the project and up to four years for a full test of the research aims.
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Who has won Cancer Cause and Prevention Research grants before
From fiscal 2021 to 2025, Cancer Cause and Prevention Research (93.393) awarded $3.6 billion across 2,517 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 81 | $107 million |
| Sloan-Kettering Institute for Cancer Research | New York | 65 | $99.1 million |
| The Trustees of Columbia University in the City of New York | New York | 48 | $85.3 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 51 | $83.1 million |
| University of North Carolina at Chapel Hill | North Carolina | 49 | $76.1 million |
Who has won Alcohol Research Programs grants before
From fiscal 2021 to 2025, Alcohol Research Programs (93.273) awarded $2.2 billion across 2,255 grant awards, an average of $974,579 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 75 | $86.5 million |
| University of North Carolina at Chapel Hill | North Carolina | 76 | $60.7 million |
| Trustees of Indiana University | Indiana | 47 | $54.8 million |
| University of California, San Diego | California | 47 | $54.5 million |
| The Medical University of South Carolina | South Carolina | 57 | $45.8 million |
Other programs behind this notice
- Minority Health and Health Disparities Research
- Nursing Research
- Research and Training in Complementary and Integrative Health
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DA-23-048 still open?
No. It closed on November 8, 2022.
Who can apply for HEAL Initiative: Research Studies to Develop and Implement Interventions to Prevent Opioid Misuse in Community Health Centers (R61/R33 Clinical Trial Required)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for HEAL Initiative: Research Studies to Develop and Implement Interventions to Prevent Opioid Misuse in Community Health Centers (R61/R33 Clinical Trial Required)?
Closed November 8, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $750,000 each.
Who has won Research and Training in Complementary and Integrative Health grants before?
The largest recipients over five fiscal years were Yale Univ, The General Hospital Corporation, Duke University. The program made 653 awards worth $575 million in that time.
Similar open grants
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
- NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)